Results 131 to 140 of about 1,093 (174)
Action of Pitolisant on the stimulant and rewarding effects of cocaine in mice
European Journal of Pharmacology, 2016 Previous studies have demonstrated that the histamine H3 receptor inverse agonist thioperamide potentiates the stimulant and rewarding effects of cocaine.
Maria Elisa Serrano Navacerrada +1 more
exaly +2 more sources
Pitolisant for the treatment of cataplexy in adults with narcolepsy [PDF]
Expert Opinion on Orphan Drugs, 2021 Gérard Meskill +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Pitolisant for treating patients with narcolepsy
Expert Review of Clinical Pharmacology, 2020Introduction: Narcolepsy is a rare sleep disorder characterized by excessive daytime sleepiness, cataplexy, disturbed nocturnal sleep, hypnagogic hallucinations, and sleep paralysis. Pitolisant is a first-in-class drug acting on histamine 3 receptors and indicated for the treatment of narcolepsy. This article aims to review pitolisant.Areas covered: In
Shuang, Li, Junyi, Yang
exaly +3 more sources
Pitolisant: Pediatric First Approval
Pediatric Drugs, 2023Pitolisant (WAKIX®), a histamine H3 receptor antagonist/inverse agonist that has been developed by Bioprojet Pharma, is approved in the EU and USA and elsewhere for use in adults with narcolepsy with or without cataplexy. In February 2023, based on clinical data in patients aged 6 to < 18 years, pitolisant received its first approval in adolescents and
openaire +2 more sources
SLEEP, 2023
Abstract Introduction WAKIX (pitolisant) is a potent and highly selective histamine 3 receptor antagonist/inverse agonist approved for the treatment of excessive daytime sleepiness or cataplexy in adult patients with narcolepsy.
Anthony Adamkovic +4 more
openaire +1 more source
Abstract Introduction WAKIX (pitolisant) is a potent and highly selective histamine 3 receptor antagonist/inverse agonist approved for the treatment of excessive daytime sleepiness or cataplexy in adult patients with narcolepsy.
Anthony Adamkovic +4 more
openaire +1 more source
Pitolisant Hydrochloride (Wakix)
Canadian Journal of Health Technologies, 2022CADTH recommends that Wakix not be reimbursed by public drug plans for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adult patients with narcolepsy. It is still not known whether Wakix offers any therapeutic benefit over other treatments used for EDS or cataplexy.
openaire +1 more source
Drug and Therapeutics Bulletin, 2017
▼Pitolisant (Wakix—Bioprojet Pharma) is a new treatment for adults with narcolepsy with or without cataplexy. It was licensed for use in the EU in March last year and has orphan drug status.1 Here, we consider the evidence for pitolisant for the treatment of narcolepsy in adults and how it fits with current management strategies.
openaire +2 more sources
▼Pitolisant (Wakix—Bioprojet Pharma) is a new treatment for adults with narcolepsy with or without cataplexy. It was licensed for use in the EU in March last year and has orphan drug status.1 Here, we consider the evidence for pitolisant for the treatment of narcolepsy in adults and how it fits with current management strategies.
openaire +2 more sources
Pitolisant and intravenous cocaine self-administration in mice
European Journal of Pharmacology, 2019Pitolisant, a selective inverse agonist for the histamine H3 receptor, is a new treatment for adults suffering from narcolepsy. Numerous studies have shown that striatal H3 receptors can modulate the activity of the dopamine mesolimbic system, a neuronal pathway that plays a crucial role in drug addiction.
Ezio Tirelli
exaly +3 more sources
Pitolisant: First Global Approval
Drugs, 2016Pitolisant (Wakix™) is an inverse agonist of the histamine H3 receptor that is being developed by Bioproject. Oral pitolisant is approved in the EU for the treatment of narcolepsy with or without cataplexy in adults. Pitolisant has received a Temporary Authorization of Use in France for this indication in case of treatment failure, intolerance or ...
openaire +4 more sources
Sleep MedicineBackground: Narcolepsy is a chronic sleep disorder characterized mainly by excessive daytime sleepiness (EDS) and cataplexy in the case of narcolepsy type 1 (NT1).
Paola Proserpio +2 more
exaly +2 more sources